A leading study has provided an unprecedented insight into the immune response after the pig-to-humon kidney xenotransplantation.
ESOT Congress conclusions presented in 2025 today, take a significant step forward to overcome the biggest challenge in xenotransplantation: rejection by human immune system.
Using state -of -the -art spatial molecular imaging, researchers mapped how human immune cells interact with pig kidney tissue in transplanted organs, revealing important early markers of rejection and potential intervention strategies. Dr. Under the leadership of Valentin Goutaudier and a colleague International Research Team (Paris Institute for Transplantation and Organ Regiment and NYU Langon Transplant Institute), the study highlights the major molecular mechanisms in the study that can shape the future of xenotransplantation.
One of the most striking discoveries was that human immune cells were found in every part of the filtering system of the pig kidney after the transplant. Researchers saw the early molecular signals of antibody-medieval rejection as soon as 10 days and at the peak at day 33, strengthening the previous conclusions that rejection begins rapidly but moves forward over time. By tracking these immune responses for 61 days, the team identified an important window for targeted medical intervention.
Our study provides the most detailed molecular map of how the human immune system is attached to a transplanted pig kidney. By pointing to specific immune cell behavior and gene manifestations, we can refine anti-free remedies and improve transpativity feasibility. ,
Dr. Valentin Goutaudier, Paris Institute for Transplantation and Organ Resinery
The innovative approach of the study used a bio -informative pipeline to distinguish human immune cells from pig structural cells, which allows accurate mapping of immune infiltration patterns. In particular, macrophages and myloid cells were the most prevalent immune cell types at all time points, further confirming their role as major intermediaries in Xenograft rejection.
When targeted medical intervention was introduced, the immune-medieval signals of rejection were successfully weakened. The novel jointly interacts with pigs kidney tissue how the immune cells jointly interact with the spatial insight, it marks a major success – paves the way to the more sophisticated anti -rejection strategies. These advances come at an important time because in living human recipients begin in 2025, the first US-based clinical trial of pig kidney transplants.
With xenotransplantation to overcome the crisis of global organ deficiency, these conclusions bring researchers to the researchers a step closer to genetically modified pig kidney to create a viable long -term solution. The next stage will focus on customizing anti-validation treatments, refining genetic modifications in donor pigs and developing initial identification protocols for monitoring and management of rejection reactions.
“Understanding specific immune interactions at a molecular level allows us to develop targeted intervention that can prevent rejection, before it increases,” Dr. Gautaudier explained. “This research performs ground work for safe and more effective pig-to-human transplant in the near future.”
As scientific progress accelerates, researchers are carefully optimistic that genetically modified pigs can become a regular transplant option within the next decade. However, regulator approval will require frequent security performance and Efficacy In diverse patient population.
